DNA methylation profiles for breast cancer subtype classifications: A translational study from microarray to...

Area of Science:

• Epigenetics
• Molecular Oncology
• Biomarker Discovery

Background:

• Breast cancer is classified into Luminal A, Luminal B, HER2-positive, and triple-negative subtypes using immunohistochemistry.
• Immunohistochemistry has limitations, potentially leading to misclassification of breast cancer subtypes.
• DNA methylation, an epigenetic modification, can alter gene expression and protein synthesis, impacting cellular function.

Purpose of the Study:

• To identify DNA methylation biomarkers for accurate breast cancer subtype classification.
• To evaluate the potential of identified biomarkers in clinical diagnostics and targeted therapy selection.

Main Methods:

• DNA extraction and bisulfite conversion from breast cancer samples.
• Microarray analysis to identify differentially methylated CpGs (DMCs).
• Methylation-specific polymerase chain reaction (MSP) for biomarker validation and subtype classification.

Main Results:

• Identified specific DMCs for each breast cancer subtype: Luminal A (ADAMTSL hypermethylation), Luminal B (ADAMTSL hypomethylation), HER2-positive (PTPRN2 hypermethylation), and TNBC (LCLAT1 hypomethylation).
• The PTPRN2 hypermethylation biomarker shows potential for identifying HER2-positive patients for targeted therapy.
• Developed MSP method achieved 75% accuracy for Luminal A and 76% for Luminal B classification.

Conclusions:

• DNA methylation biomarkers can accurately classify breast cancer subtypes, overcoming limitations of current methods.
• The identified PTPRN2 methylation biomarker offers a promising tool for HER2-positive breast cancer diagnosis and treatment.
• The developed MSP assay presents a viable diagnostic tool for Luminal A and Luminal B breast cancer classification.